Welcome to our dedicated page for Abbott Labs news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Labs stock.
Abbott Laboratories (NYSE: ABT) generates a steady flow of news across diagnostics, medical devices, nutritionals and branded generic medicines, reflecting its role as a global healthcare company serving people in more than 160 countries. News coverage on this page highlights regulatory milestones, product launches, clinical data, corporate actions and community initiatives that shape Abbott’s business and its impact on patients.
Recent announcements include FDA approvals and clearances for cardiovascular and structural heart technologies, such as the Volt PFA System for treating atrial fibrillation and the Amplatzer Piccolo Delivery System for minimally invasive closure of patent ductus arteriosus in premature infants. Abbott also reports developments in diabetes care and metabolic health, including enhancements to its Libre app through the Libre Assist feature, which uses generative AI and continuous glucose monitoring data to help people living with diabetes understand how food choices may affect glucose levels, and the expansion of its Lingo over-the-counter continuous glucose monitor to additional mobile platforms.
Investors and observers will also find news about Abbott’s nutrition business, such as new Ensure Max Protein shakes aimed at supporting muscle health for active and older adults, as well as information on public health partnerships and community programs like the "We Give Blood" competition with the Big Ten Conference and the HeartMates community for people with heart health challenges. Corporate updates include dividend declarations and increases, as well as the announced Agreement and Plan of Merger to acquire Exact Sciences Corporation, which would expand Abbott’s presence in cancer screening and precision oncology diagnostics.
This news feed provides a centralized view of Abbott’s latest announcements, allowing readers to follow developments in its key business segments and understand how new products, regulatory events and strategic transactions may influence the company over time.
Abbott (NYSE: ABT) and Flatiron Health integrated Abbott's Precision Oncology portfolio into Flatiron's OncoEMR on March 30, 2026. The integration lets clinicians order Abbott tests and receive results inside the OncoEMR workflow, expanding access across Flatiron's network of 1,600+ community cancer centers and 4,700 providers.
This single, unified experience covers Oncotype DX Breast Recurrence Score®, OncoExTra®, Oncodetect®, and Riskguard®, aiming to reduce administrative burden and accelerate informed treatment decisions in community oncology settings.
Abbott (NYSE: ABT) will report first-quarter 2026 financial results on Thursday, April 16, 2026, before the market opens. The results will be followed by a live earnings conference call and webcast at 8:00 a.m. Central / 9:00 a.m. Eastern.
According to the company, the webcast will be accessible via Abbott's investor relations website and an archived edition will be available later that day.
Abbott (NYSE: ABT) launched "The (Second) Talk" campaign on March 24, 2026, reuniting John Stamos and Jodie Sweetin to encourage colorectal cancer screening for adults 45 and older.
The campaign promotes the FDA-approved Cologuard test as a noninvasive, at-home screening option; a clinical study reports Cologuard Plus detected 95% of colon cancers.
Abbott (NYSE: ABT) completed its acquisition of Exact Sciences on March 23, 2026, making Exact Sciences a wholly owned Abbott subsidiary and ending Exact Sciences' Nasdaq trading on March 20, 2026.
The deal adds a comprehensive cancer screening and precision oncology portfolio — including Cologuard, Oncotype DX, Oncodetect and Cancerguard — and positions Abbott to serve millions more and lead in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segments.
Abbott (NYSE: ABT) expects to close its acquisition of Exact Sciences on March 23, 2026 after receiving all required regulatory clearances. The deal adds cancer screening and precision oncology capabilities, including Cologuard and Oncotype DX, and is expected to contribute ~$3 billion of incremental sales in 2026.
The transaction is projected to accelerate Abbott's 2026 sales growth by ~0.5 percentage points and dilute 2026 adjusted EPS by ~$0.20.
Abbott (NYSE: ABT) reported results from the FreeDM2 randomized controlled trial showing that people with Type 2 diabetes on basal insulin using FreeStyle Libre continuous glucose monitoring (CGM) achieved better glucose control versus fingersticks at four months.
Key findings: HbA1c fell 0.6% (p<0.001) and participants spent ~2.5 more hours/day in the 70–180 mg/dL healthy range (a 10.4% increase). An Italian interventional study of 88 people showed similar benefits at three months.
Abbott (NYSE: ABT) and Real Madrid launched year two of the Abbott Dream Team, a nationwide youth program for 18–19-year-old soccer players offering free selection events, health and nutrition education, and on-field development led by Real Madrid coaches. 16 finalists will receive an all‑expenses‑paid training trip to Madrid and return to lead local health sessions.
Selection events run May–June in Miami, Washington D.C., Houston, Kansas City, Los Angeles and Chicago; participants register at AbbottDreamTeam.com. Marcelo will join as a mentor.
Summary not available.
Exact Sciences (NASDAQ: EXAS) stockholders voted to approve the proposed acquisition by Abbott (NYSE: ABT) at a special meeting held February 20, 2026. Preliminary results showed >99% of votes cast, representing ~67% of outstanding shares as of the January 9, 2026 record date, voted in favor.
Subject to satisfaction or waiver of remaining closing conditions, the transaction is expected to close before the end of the second calendar quarter of 2026. According to the company, each Exact Sciences share will receive $105.00 in cash upon completion, without interest and subject to applicable withholding taxes. Final voting results will be reported on Form 8-K filed with the SEC.
Abbott (NYSE: ABT) declared a quarterly common dividend of $0.63 per share, payable May 15, 2026, to shareholders of record at the close of business April 15, 2026.
This is the 409th consecutive quarterly dividend since 1924 and continues Abbott's streak of increasing dividends for 54 consecutive years; Abbott remains in the S&P 500 Dividend Aristocrats Index.